| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10.18 | Visa Readies B2B Connect for Market | 379 | Business Wire | Visa's Distributed Ledger Platform Provides Groundbreaking "Digital Identity" for Clients; IBM and Bottomline Technologies Announced as New Partners for Commercial Launch Visa... ► Artikel lesen | |
| 21.10.18 | SOLO-1 Phase 3 Trial Demonstrates LYNPARZA (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer | 96 | Business Wire | 60 Percent of Patients Receiving LYNPARZA Remained Progression-Free at Three Years Compared to 27 Percent on Placebo Following Platinum-Based Chemotherapy LYNPARZA Is the Only PARP... ► Artikel lesen | |
| 21.10.18 | Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma | 175 | Business Wire | Updated results presented at ESMO support planned submission of NDA in U.S. in 2019 Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202... ► Artikel lesen | |
| 21.10.18 | Servier and Taiho Oncology Announce Phase III LONSURF Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer | 90 | Business Wire | Positive Results from TAGS presented at ESMO 2018 Congress and Published in The Lancet Oncology Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co.,... ► Artikel lesen | |
| 21.10.18 | Genentech's Investigational Personalized Medicine Entrectinib Shrank Tumors in People with NTRK Fusion-Positive Solid Tumors | 119 | Business Wire | - Entrectinib showed response irrespective of tumor type or spread to the central nervous system (CNS) - - Data will be submitted to global regulatory authorities, including the U.S.... ► Artikel lesen | |
| 21.10.18 | Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting | 124 | Business Wire | -- FINCH 2 Study Results Demonstrate Significant Improvement in Rheumatoid Arthritis Signs, Symptoms and Health-Related Quality of Life - Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 4.932 |
| PALANTIR TECHNOLOGIES | 4.073 |
| NEL | 3.949 |
| TUI | 2.901 |
| BAYER | 2.683 |
| NVIDIA | 2.568 |
| DEUTSCHE BANK | 2.239 |
| INFINEON | 2.158 |
| BYD | 2.055 |
| SUPER MICRO COMPUTER | 1.968 |
| MERCEDES-BENZ | 1.898 |
| BIONTECH | 1.873 |
| RHEINMETALL | 1.849 |
| DEUTSCHE LUFTHANSA | 1.787 |
| PLUG POWER | 1.703 |
| VARTA | 1.644 |
| TESLA | 1.625 |
| RWE | 1.588 |
| AIXTRON SE | 1.547 |
| RENK GROUP | 1.465 |
| COMMERZBANK | 1.430 |
| SIEMENS ENERGY | 1.392 |
| ALLIANZ | 1.368 |
| VOLKSWAGEN | 1.343 |
| BASF | 1.333 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
